It’s in the Genes

CRISPR technologies provide much needed cures, but at a very high cost. Can we maintain the UK’s momentum in gene therapy with technologies like viral vectors?


JONATHAN APPLEBY | Chief Scientific Officer | Cell and Gene Therapy Catapult (CGT Catapult)


DANIEL SMITH | Chief Scientific Officer & Industry Professor, School of Life Science | Cobra Biologics & University of Warwick
JESÚS ZURDO | Global Head Bioproduction | Horizon Discovery
MIKE SNOWDEN | Senior Vice President Discovery Sciences, Biopharmaceuticals R&D  | AstraZeneca
NATALIA NOVAC | Senior Director, Emerging Technology & Innovation, Corporate Business Development | Eli Lilly
ANNA PERDRIX ROSELL | Co-founder and Managing Director | Sixfold Bioscience